Corcept Therapeutics upgraded by Truist with a new price target
$CORT
Biotechnology: Pharmaceutical Preparations
Health Care
Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/31/2025 | $30.00 | Peer Perform → Underperform | Wolfe Research |
| 12/16/2025 | Neutral | UBS | |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 11/6/2023 | $29.00 → $38.00 | Hold → Buy | Truist |
| 4/11/2023 | $25.00 | Market Perform | SVB Securities |
| 4/4/2023 | $27.00 | Overweight | Piper Sandler |
| 2/15/2023 | $35.00 → $22.00 | Buy → Hold | Jefferies |
| 8/1/2022 | $30.00 | Buy → Hold | Truist |
Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00
UBS initiated coverage of Corcept Therapeutics with a rating of Neutral
Wolfe Research initiated coverage of Corcept Therapeutics with a rating of Peer Perform
2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals' marketing of a generic version of Korlym® does not infringe two of Corcept's patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing's syndrome. The ruling affirms a December 2023 verdict by the Federal D
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
10-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.
Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)